The global market for SGLT2 inhibitors treatment is poised for substantial growth, with projections indicating a robust upward trajectory from 2021 to 2031. SGLT2 inhibitors, renowned for their role in glucose reabsorption from the kidneys, are anticipated to fuel this growth by contributing to lower blood glucose levels in patients.
The escalating demand for antidiabetic drugs, particularly SGLT2 inhibitors, is a significant driver of market expansion. As the prevalence of type 2 diabetes continues to surge worldwide, the consumption of these inhibitors has seen a remarkable uptick. This surge in demand is further propelled by the ever-growing population afflicted by diabetes, positioning SGLT2 inhibitors as a cornerstone in the management of this chronic condition.
Get your PDF Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-14054
The global prevalence of diabetes is not only driving the market growth but also reshaping the landscape of diabetic care, underscoring the critical need for effective treatment options such as SGLT2 inhibitors. With their proven efficacy in managing blood glucose levels and reducing cardiovascular risks, these inhibitors are poised to elevate the standards of diabetic care to unprecedented levels.
As we progress into the forecast period, the market for SGLT2 inhibitors treatment is set to witness exponential growth, driven by evolving healthcare needs and the relentless pursuit of innovation in diabetic therapeutics.
The factors driving demand for the SGLT2 inhibitors treatment market. Here’s a breakdown of the key points:
- Rising Diabetes Prevalence: The global diabetic population is exploding, with estimates suggesting a jump from 2.8% in 2000 to a projected 4.4% by 2030 [source: World Health Organization data, as mentioned in your text]. This surge in diabetes fuels the need for effective treatments like SGLT2 inhibitors.
- Lifestyle Factors: The growing trend of unhealthy lifestyles marked by obesity and physical inactivity significantly contributes to diabetes. This creates a larger patient pool potentially needing SGLT2 inhibitors.
- Patient Preference for Convenience: Easy-to-use treatment options are always preferred by patients. The relatively simple administration of SGLT2 inhibitors compared to some other diabetes medications can be a significant advantage.
- Post-COVID Complications: The emergence of COVID-19 has added another layer of complexity. Diabetes is a known risk factor for severe COVID-19 complications, and SGLT2 inhibitors may play a role in managing these complications, further increasing demand.
- New Combination Drugs: The development of new SGLT2 inhibitor drugs combined with other diabetes medications offers a broader range of treatment options, potentially attracting more patients and healthcare providers.
- High Obesity Rates in Developed Regions: The high prevalence of morbid obesity in developed countries like the US and Europe is a significant driver as obesity is a major risk factor for diabetes, and consequentially, a potential market for SGLT2 inhibitors.
Get Customization on This Report: https://www.futuremarketinsights.com/customization-available/rep-gb-14054
Some of the key players operating in the SGLT2 Inhibitors Treatment Market are:
- Eli Lilly and Company (The U.S),
- C.H. Boehringer Sohn AG & Ko. KG (Germany),
- Johnson & Johnson (The U.S),
- AstraZeneca plc (UK),
- The Merck Group (Germany),
- Pfizer Inc. (The U.S),
- Tecnimede Group (The U.S),
- Unichem Laboratories Ltd. (India), and
- Edifício Bluepharma (Portugal).
Key Segment
By Product Type:
- Single Cap
- Double Cap
By End User:
- Hospitals
- Clinics
- Diagnostic Centre’s
- Others
By Application:
- Blood Collection,
- Blood Transfusion
- Infusion
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
Get Complete Full Report: https://www.futuremarketinsights.com/checkout/14054
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
